These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38592331)

  • 1. Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.
    Menachem A; Alteber Z; Cojocaru G; Fridman Kfir T; Blat D; Leiderman O; Galperin M; Sever L; Cohen N; Cohen K; Granit RZ; Vols S; Frenkel M; Soffer L; Meyer K; Menachem K; Galon Tilleman H; Morein D; Borukhov I; Toporik A; Perpinial Shahor M; Tatirovsky E; Mizrachi A; Levy-Barda A; Sadot E; Strenov Y; Eitan R; Jakobson-Setton A; Yanichkin N; Ferre P; Ophir E
    Cancer Immunol Res; 2024 Jun; 12(6):687-703. PubMed ID: 38592331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting interleukin 18 with interleukin 18 binding protein.
    Dinarello CA
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i17-20. PubMed ID: 11053080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
    Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
    Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique bivalent binding and inhibition mechanism by the yatapoxvirus interleukin 18 binding protein.
    Krumm B; Meng X; Wang Z; Xiang Y; Deng J
    PLoS Pathog; 2012; 8(8):e1002876. PubMed ID: 22927815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targets for interleukin 18 binding protein.
    Dinarello CA
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii18-24. PubMed ID: 11890646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production.
    Du G; Ye L; Zhang G; Dong Q; Liu K; Tian J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1727-36. PubMed ID: 22699929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer.
    Guo X; Zheng L; Jiang J; Zhao Y; Wang X; Shen M; Zhu F; Tian R; Shi C; Xu M; Li X; Peng F; Zhang H; Feng Y; Xie Y; Xu X; Jia W; He R; Xie C; Hu J; Ye D; Wang M; Qin R
    Clin Cancer Res; 2016 Dec; 22(23):5939-5950. PubMed ID: 27297583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura.
    Shan NN; Zhu XJ; Peng J; Qin P; Zhuang XW; Wang HC; Hou M
    Br J Haematol; 2009 Mar; 144(5):755-61. PubMed ID: 19077159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
    Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
    Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study.
    Deser SB; Bayoglu B; Besirli K; Cengiz M; Arapi B; Junusbekov Y; Dirican A; Arslan C
    Heart Vessels; 2016 Jun; 31(6):976-84. PubMed ID: 26438531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
    Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
    Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.
    Carbotti G; Barisione G; Orengo AM; Brizzolara A; Airoldi I; Bagnoli M; Pinciroli P; Mezzanzanica D; Centurioni MG; Fabbi M; Ferrini S
    Clin Cancer Res; 2013 Sep; 19(17):4611-20. PubMed ID: 23873689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small non-interface surface epitope in human IL18 mediates the dynamics and self-assembly of IL18-IL18BP heterodimers.
    Yazıcı YY; Belkaya S; Timucin E
    Comput Struct Biotechnol J; 2023; 21():3522-3531. PubMed ID: 37484491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
    Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
    Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.